HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment

Abstract

The main method of treatment patients with disseminated gastric cancer is drug therapy. Trastuzumab has proven its efficacy in therapyHER2-positive gastric cancer in combination with chemotherapy. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to chemotherapy significantly improved overall survival and, therefore, is required to treat these patients.

Keywords

• her2-positive gastric and gastro-oesophageal junction cancer
• her2-status
• trastuzumab
• target therapy